Pacira to Report 2025 Financial Results on Thursday February 26, 2026

Core Viewpoint - Pacira BioSciences, Inc. is set to report its fourth quarter and full year financial results for 2025 on February 26, 2026, after U.S. market close, followed by a live conference call and webcast [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL®: a long-acting local analgesic approved for various postsurgical pain management techniques [3] - ZILRETTA®: an extended-release injectable for managing osteoarthritis knee pain [3] - iovera®: a handheld device providing immediate, long-acting, drug-free pain control through cold temperature application [3] - Pacira is advancing a pipeline of clinical-stage assets for musculoskeletal pain, with its leading candidate, PCRX-201, in Phase 2 clinical development for knee osteoarthritis [3]